Literature DB >> 324622

Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.

D L Ahmann, M J O'Connell, H F Bisel, J H Edmonson, R G Hahn, S Frytak.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 324622

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  3 in total

1.  Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells.

Authors:  I Pályi; J Bence; K Szikla; L Hullán
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.

Authors:  E Institóris; K Szikla; L Otvös; F Gál
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Alkylation by 1,2:5,6-dianhydrogalactitol of deoxyribonucleic acid and guanosine.

Authors:  E Institóris; J Tamás
Journal:  Biochem J       Date:  1980-03-01       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.